More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Case Western Reserve University recently scored a $1.125 million grant from the National Science Foundation to help fuel its work, with a focus on MRI.
Researchers examined data from more than 21,000 patients treated from 1997 to 2018, publishing their findings in the Journal of the American Heart Association.
“Cardiothoracic imaging continues to evolve, fueled by technical innovations such as dynamic chest radiography, digital tomosynthesis and dark-field radiography," one radiologist said.
